Alfred H Schinkel

List of Publications by Year
in descending order

157	16,279	19657 61	16183 124
papers	citations	h-index	g-index

157	157	157	11937
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews, 2003, 55, 3-29.	13.7	1,259
2	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews, 2012, 64, 138-153.	13.7	903
3	MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine. Cell, 1996, 87, 507-517.	28.9	858
4	P-Glycoprotein, a gatekeeper in the bloodâ€“brain barrier. Advanced Drug Delivery Reviews, 1999, 36, 179-194.	13.7	821
5	The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15649-15654.	7.1	759
6	The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology, 1997, 8, 161-170.	9.6	413
7	Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 510-515.	2.5	398
8	The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nature Medicine, 2005, 11, 127-129.	30.7	376
9	Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 2002, 1, 417-25.	4.1	371
10	The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients. Cancer Research, 2005, 65, 2577-2582.	0.9	338
11	Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. Journal of Clinical Investigation, 2000, 105, 279-285.	8.2	334
12	Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. Journal of Clinical Investigation, 2012, 122, 519-528.	8.2	321
13	Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. Journal of Clinical Investigation, 1999, 104, 1441-1447.	8.2	314
14	The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Letters, 1994, 354, 263-266.	2.8	260
15	Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 144-152.	2.5	258
16	Substantial excretion of digoxin via the intestinal mucosa and prevention of longâ€term digoxin accumulation in the brain by the mdrla Pâ€glycoprotein. British Journal of Pharmacology, 1996, 119, 1038-1044.	5.4	248
17	Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles. Cancer Research, 2004, 64, 5804-5811.	0.9	222
18	Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene. Molecular and Cellular Biology, 2001, 21, 5471-5477.	2.3	220

#	Article	IF	Citations
19	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. Journal of Clinical Investigation, 2007, 117, 3583-3592.	8.2	210
20	Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice. Advanced Drug Delivery Reviews, 2009, 61, 14-25.	13.7	204
21	The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Research, 2003, 63, 6447-52.	0.9	199
22	Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids, 2002, 16, 2295-2301.	2.2	198
23	Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B 2) into Milk. Molecular and Cellular Biology, 2007, 27, 1247-1253.	2.3	191
24	Organic anion transporting polypeptide 1a/1bâ€“knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. Journal of Clinical Investigation, 2010, 120, 2942-2952.	8.2	191
25	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International Journal of Cancer, 2005, 116, 824-829.	5.1	189
26	Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	3.4	177
27	The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends in Pharmacological Sciences, 2006, 27, 10-16.	8.7	177
28	P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir. Molecular Pharmacology, 2001, 59, 806-813.	2.3	171
29	Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. Molecular Cancer Therapeutics, 2010, 9, 319-326.	4.1	171
30	Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. Aids, 2000, 14, 237-242.	2.2	164
31	Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment. Clinical Cancer Research, 2009, 15, 2344-2351.	7.0	158
32	Brain accumulation of sunitinib is restricted by Pâ€glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International Journal of Cancer, 2012, 130, 223-233.	5.1	145
33	Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver. Molecular Pharmacology, 2005, 67, 1765-1771.	2.3	144
34	Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 29-32.	2.2	139
35	Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis, 2005, 27, 123-130.	2.8	132
36	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the Pâ€glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer, 2014, 134, 1484-1494.	5.1	127

#	Article	IF	Citations
37	P-glycoprotein ABCB1: a major player in drug handling by mammals. Journal of Clinical Investigation, 2013, 123, 4131-4133.	8.2	127
38	Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice. Stem Cells, 2005, 23, 1059-1065.	3.2	126
39	Modulation of oral bioavailability of anticancer drugs: from mouse to man. European Journal of Pharmaceutical Sciences, 2000, 12, 103-110.	4.0	125
40	Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1). Drug Metabolism and Disposition, 2009, 37, 277-281.	3.3	117
41	Oral Availability and Brain Penetration of the B-RAF^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. Molecular Pharmaceutics, 2012, 9, 3236-3245.	4.6	113
42	Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice. Clinical Cancer Research, 2013, 19, 821-832.	7.0	113
43	A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice. Pharmacological Reviews, 2011, 63, 390-410.	16.0	108
44	Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes. Molecular Pharmacology, 2008, 73, 1029-1036.	2.3	106
45	Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. Hepatology, 2017, 66, 1631-1643.	7.3	100
46	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Research, 2003, 63, 1339-44.	0.9	89
47	Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics. Clinical Cancer Research, 2006, 12, 6125-6132.	7.0	88
48	Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity. Cancer Research, 2009, 69, 8996-9002.	0.9	88
49	Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition. Advances in Cancer Research, 2015, 125, 1-41.	5.0	83
50	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide. Clinical Cancer Research, 2010, 16, 130-140.	7.0	79
51	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharmaceutical Research, 2015, 32, 37-46.	3.5	79
52	Pâ€glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer, 2013, 132, 2439-2447.	5.1	75
53	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Molecular Cancer Therapeutics, 2009, 8, 3350-3359.	4.1	74
54	Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. British Journal of Pharmacology, 1998, 124, 416-424.	5.4	71

#	Article	IF	Citations
55	Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. Journal of the National Cancer Institute, 1998, 90, 1161-1166.	6.3	69
56	P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 710-717.	2.5	68
57	Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends in Pharmacological Sciences, 2012, 33, 100-108.	8.7	68
58	Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemotherapy and Pharmacology, 2005, 56, 344-350.	2.3	67
59	Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters. Molecular Pharmacology, 2010, 77, 687-694.	2.3	67
60	Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone. Drug Metabolism and Disposition, 2009, 37, 129-136.	3.3	63
61	Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Bloodâ^'Brain Barrier. Molecular Pharmaceutics, 2011, 8, 571-582.	4.6	63
62	Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. Drug Metabolism and Disposition, 2011, 39, 729-735.	3.3	62
63	Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam. Drug Metabolism and Disposition, 2009, 37, 2305-2313.	3.3	61
64	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 2015, 75, 2729-2736.	0.9	59
65	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacological Research, 2015, 102, 200-207.	7.1	59
66	Human OATP1B1, OATP1B3 and OATP1A2 can mediate thein vivouptake and clearance of docetaxel. International Journal of Cancer, 2015, 136, 225-233.	5.1	58
67	Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metabolism and Disposition, 2008, 36, 631-640.	3.3	55
68	Pharmacokinetic Assessment of Multiple ATP-binding Cassette Transporters: The Power of Combination Knockout Mice. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 136-145.	3.4	54
69	P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin. Antimicrobial Agents and Chemotherapy, 2008, 52, 1034-1039.	3.2	53
70	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharmaceutical Research, 2015, 32, 2205-2216.	3.5	53
71	High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel. Clinical Cancer Research, 2011, 17, 294-301.	7.0	49
72	Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast) Tj ETQq0 0 0 rgBT /Overlock 10 T 7-Hydroxymethotrexate. Drug Metabolism and Disposition, 2011, 39, 1338-1344.	3.3	48

#	Article	IF	Citations
73	Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 486-494.	2.5	48
74	Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors. Drug Metabolism and Disposition, 2009, 37, 917-923.	3.3	47
75	Individual and combined roles of CYP3A, Pâ€glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer, 2010, 127, 2959-2964.	5.1	47
76	Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2019, 411, 5331-5345.	3.7	47
77	The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice. Drug Resistance Updates, 2016, 27, 72-88.	14.4	46
78	How important is intestinal cytochrome P450 3A metabolism?. Trends in Pharmacological Sciences, 2009, 30, 223-227.	8.7	44
79	MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4. Drug Metabolism and Disposition, 2005, 33, 892-895.	3.3	43
80	Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 4090-4096.	2.3	43
81	In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. International Journal of Cancer, 2014, 135, 1700-1710.	5.1	43
82	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research, 2017, 120, 43-50.	7.1	43
83	Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clinical Pharmacokinetics, 2020, 59, 1501-1520.	3.5	43
84	Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB Journal, 2009, 23, 224-231.	0.5	42
85	A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2984-2990.	2.3	40
86	Liquid chromatographyâ€“tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2016, 118, 123-131.	2.8	39
87	P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib MetaboliteN-Desethyl Sunitinib. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 164-173.	2.5	36
88	Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure. Molecular Pharmacology, 2013, 83, 919-929.	2.3	34
89	OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice. Molecular Cancer Therapeutics, 2014, 13, 492-503.	4.1	33
90	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drugâ€“Drug Interactions in Vivo. Molecular Pharmaceutics, 2015, 12, 4259-4269.	4.6	32

#	Article	IF	Citations
91	Pâ€glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450â€3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International Journal of Cancer, 2018, 143, 2029-2038.	5.1	32
92	Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. Drug Metabolism and Disposition, 2014, 42, 1301-1313.	3.3	31
93	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research, 2018, 129, 414-423.	7.1	31
94	Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. American Journal of Physiology - Cell Physiology, 2007, 292, C2204-C2212.	4.6	30
95	P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. Molecular Pharmaceutics, 2019, 16, 3842-3852.	4.6	30
96	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. Clinical Cancer Research, 2014, 20, 3133-3145.	7.0	29
97	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacological Research, 2019, 146, 104297.	7.1	29
98	In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Molecular Cancer Therapeutics, 2007, 6, 3307-3313.	4.1	27
99	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. European Journal of Pharmaceutical Sciences, 2009, 36, 565-571.	4.0	27
100	Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. International Journal of Cancer, 2016, 138, 758-769.	5.1	26
101	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Molecular Pharmaceutics, 2017, 14, 3258-3268.	4.6	25
102	P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacological Research, 2018, 137, 47-55.	7.1	25
103	Organic Anion-Transporting Polypeptides 1a/1b Control the Hepatic Uptake of Pravastatin in Mice. Molecular Pharmaceutics, 2012, 9, 2497-2504.	4.6	24
104	Liquid chromatographyâ€“tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 905, 150-154.	2.3	23
105	Liquid chromatographyâ€“tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography, 2014, 28, 1366-1370.	1.7	22
106	Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites. Molecular Pharmacology, 2014, 85, 520-530.	2.3	22
107	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis, 2018, 161, 136-143.	2.8	22
108	P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine. Molecular Pharmacology, 2012, 82, 636-644.	2.3	20

#	Article	IF	Citations
109	P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Molecular Pharmaceutics, 2015, 12, 3714-3723.	4.6	20
110	Genetically modified mouse models for oral drug absorption and disposition. Current Opinion in Pharmacology, 2013, 13, 853-858.	3.5	18
111	Liquid chromatographyâ€“tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquidâ€“liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1012-1013, 118-123.	2.3	18
112	P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids. International Journal of Pharmaceutics, 2017, 521, 365-373.	5.2	18
113	Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 120-130.	4.3	17
114	An Integrated Pharmacokinetic Model for the Influence of CYP3A4 Expression on the In Vivo Disposition of Lopinavir and Its Modulation by Ritonavir. Journal of Pharmaceutical Sciences, 2011, 100, 2508-2515.	3.3	16
115	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 204-208.	2.3	16
116	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Molecular Pharmaceutics, 2018, 15, 5124-5134.	4.6	15
117	Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 451-466.	4.5	15
118	Liquid chromatographyâ€“tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 626-629.	2.8	14
119	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British Journal of Pharmacology, 2020, 177, 3060-3074.	5.4	14
120	Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1. Toxicology and Applied Pharmacology, 2017, 329, 18-25.	2.8	13
121	Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein. Pharmaceutical Research, 2019, 36, 158.	3.5	12
122	Extrahepatic metabolism of ibrutinib. Investigational New Drugs, 2021, 39, 1-14.	2.6	12
123	Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 855-869.	2.3	12
124	The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. Drug and Alcohol Dependence, 2021, 227, 108984.	3.2	12
125	Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2751-2759.	2.3	11
126	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	5.2	11

#	Article	IF	Citations
127	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1174, 122718.	2.3	11
128	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1102-1103, 167-172.	2.3	10
129	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International Journal of Pharmaceutics, 2019, 556, 172-180.	5.2	10
130	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International Journal of Pharmaceutics, 2020, 573, 118842.	5.2	10
131	Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114225.	2.8	10
132	Liquid chromatographyâ€“tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 174-177.	2.3	9
133	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1110-1111, 116-123.	2.3	9
134	No relation between docetaxel administration route and highâ€grade diarrhea incidence. Pharmacology Research and Perspectives, 2020, 8, e00633.	2.4	9
135	ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacological Research, 2022, 178, 105954.	7.1	9
136	Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1147, 122131.	2.3	8
137	Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice. Toxicology and Applied Pharmacology, 2020, 401, 115072.	2.8	8
138	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 300-305.	2.3	7
139	Pâ€glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGFâ€Î²2 signaling pathway inhibitor galunisertib. International Journal of Cancer, 2020, 146, 1631-1642.	5.1	7
140	Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1144, 122098.	2.3	7
141	Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. Journal of Pharmaceutical and Biomedical Analysis, 2020, 190, 113516.	2.8	6
142	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. Molecular Cancer Therapeutics, 2021, 20, 1173-1182.	4.1	6
143	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacological Research, 2021, 172, 105850.	7.1	6
144	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics, 2021, 13, 1761.	4.5	6

#	Article	IF	Citations
145	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular Pharmaceutics, 2021, 18, 4371-4384.	4.6	6
146	Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis. International Journal of Clinical and Experimental Pathology, 2015, 8, 5252-62.	0.5	6
147	Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1). Pharmacogenetics and Genomics, 2002, 12, 589-590.	5.7	5
148	Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1122-1123, 78-82.	2.3	5
149	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. European Journal of Pharmaceutical Sciences, 2021, 159, 105740.	4.0	5
150	What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters. Pharmacological Research, 2017, 123, 144.	7.1	4
151	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Pharmacological Research, 2022, 178, 106137.	7.1	4
152	Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. Pharmaceuticals, 2022, 15, 860.	3.8	3
153	Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib. Journal of Pharmaceutical Sciences, 2022, 111, 495-504.	3.3	2
154	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals, 2021, 14, 1087.	3.8	2
155	Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. Frontiers in Pharmacology, 2022, 13, 855000.	3.5	2
156	ABCB1 restricts brain accumulation of the novel RORÎ³ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 135-146.	4.3	1
157	Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 197-207.	4.3	0